Cat. No. ARG0268
The USP22 Knockout HCCLM3 Cell Line is a CRISPR/Cas9-edited human hepatocellular carcinoma cell line with targeted disruption of the USP22 deubiquitinase gene. USP22, a component of the SAGA complex, regulates histone ubiquitination and transcriptional activation of genes linked to proliferation and stemness via pathways such as Wnt/??-catenin and PI3K/AKT. This knockout model in the highly metastatic HCCLM3 background enables dissection of USP22's role in tumor invasion and metastasis. Ideal for studying epigenetic regulation, oncogenic signaling, and drug responses, this cell line supports assays including migration, apoptosis, and reporter gene analyses. Investigators can use it to screen for USP22 inhibitors and explore crosstalk between USP22 and key factors like c-Myc, cyclin D1, and p21.
| Host Cell | HCCLM3 |
| Age | 39 years |
| Gene Name | Usp22 |
| Gene Identifier | NCBI Gene ID 23326 |
| Temperature | 37°C |
| Atmosphere | 5% CO₂ |
| Sterility testing | Daily monitoring confirms that the cells are free from bacterial, yeast, and fungal contamination. |
| Mycoplasma testing | Negative for mycoplasma through PCR analysis |
| Pathogens | Cells tested negative for HIV-1, HBV, and HCV. |
Intended Use: This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.
Disclaimer: Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability.
By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use.
This product is provided "AS IS". For Research Use Only. Not for human or animal therapeutic use.
The USP22 Knockout HCCLM3 Cell Line is a CRISPR/Cas9-edited knockout cell line featuring targeted disruption of the USP22 gene in the HCCLM3 human hepatocellular carcinoma background. This stable loss-of-function model enables robust investigation of USP22-dependent pathways without the limitations of transient gene silencing. It provides a defined platform for studying gene function in a metastatic tumor context.
HCCLM3, derived from the highly metastatic MHCC97-H line, is a well-characterized model for studying hepatocellular carcinoma invasion and metastasis. This cell line recapitulates aggressive tumor behavior, making it ideal for assessing the impact of USP22 knockout on metastatic potential, proliferation, and interaction with the microenvironment.
USP22 is a deubiquitinase core component of the SAGA transcriptional coactivator complex, functioning within the deubiquitination module alongside GCN5, ADA2, ADA3, SGF29, TAF5L, TAF6L, ATXN7, ATXN7L3, and SUPT20H. It catalyzes removal of ubiquitin from histones H2A at K119 and H2B at K120, facilitating transcriptional activation. USP22 is regulated by upstream factors including c-Myc, ??-catenin/TCF, NF-??B, AP-1, EGF, and TGF-??, and controls downstream effectors such as c-Myc, cyclin D1, p21, Bax, and Bcl-2. Consequently, USP22 integrates oncogenic pathways like Wnt/??-catenin, NF-??B, TGF-??, and PI3K/AKT, influencing proliferation, cell cycle progression, apoptosis, and stemness.
In hepatocellular carcinoma, USP22 upregulation enhances tumor growth and metastasis by promoting oncogenic transcription through histone deubiquitination. The HCCLM3 USP22 knockout cell line enables detailed analysis of how USP22 loss affects key signaling nodes such as ??-catenin, TCF/LEF, NF-??B p65, PI3K, AKT, mTOR, cyclin D1, and p21. This model is particularly suited for elucidating the epigenetic mechanisms driving the malignant phenotype in metastatic liver cancer.
This knockout line supports diverse applications, including investigating USP22’s role in proliferation, invasion, and metastasis via Transwell assays, flow cytometry, and immunofluorescence; epigenetic studies using Western blotting, RT-qPCR, RNA-seq, and ChIP-qPCR; drug sensitivity testing; deubiquitinase inhibitor screening; and Wnt/??-catenin reporter assays to probe pathway crosstalk. For further information, please contact Ascent Research.
